Relay Therapeutics Q1 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate, Sales $10.007M Beat $87.500K Estimate
Relay Therapeutics Q1 2024 GAAP EPS $(0.62) Beats $(0.71) Estimate, Sales $10.007M Beat $87.500K Estimate
Relay Therapeutics2024年第一季度GAAP每股收益美元（0.62美元）超過預期（0.71美元），銷售額10007萬美元超過預期的8750萬美元
Relay Therapeutics (NASDAQ:RLAY) reported quarterly losses of $(0.62) per share which beat the analyst consensus estimate of $(0.71) by 12.68 percent. This is a 20.51 percent increase over losses of $(0.78) per share from the same period last year. The company reported quarterly sales of $10.007 million which beat the analyst consensus estimate of $87.500 thousand by 11.34K percent. This is a 4.33K percent increase over sales of $226.000 thousand the same period last year.
Relay Therapeutics（納斯達克股票代碼：RLAY）公佈的季度虧損爲每股0.62美元，比分析師普遍預期的0.71美元（0.71美元）高出12.68％。這比去年同期每股虧損0.78美元（0.78美元）增長了20.51％。該公司公佈的季度銷售額爲1000.7萬美元，比分析師普遍預期的87,500美元高出11.34萬個百分點。這比去年同期的22.6萬美元銷售額增長了43.3萬個百分點。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。